Recent Updates in Refractory Metastatic Colorectal Cancer Management

Recent Updates in Refractory Metastatic Colorectal Cancer Management

Systemic Therapy in LA-SCCHN
French Subtitles Available in Video Player
Download Transcript (EN)
Download Transcript (FR)
Icon Objectives

Learning Objectives

  1. Educate Canadian Oncologists on emerging therapies in the refractory setting, especially in later lines of therapy.
  2. Characterize the current treatment algorithm for mCRC and how this would change with the availability of new treatments.
  3. Share best practices from scientific leaders for selection of later line treatments and implementation into clinical practice.
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Moderators

Dr. Sharlene Gill

Icon Chair Speaker

Speakers

Dr. Eric Chen

Dr. Petr Kavan

Studies / Trials Discussed

  • FRESCO-2 study
  • Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
  • SUNLIGHT study
  • Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study

This program has been made possible through unrestricted support from Taiho.

Studies/trials discussed:

  • FRESCO-2 study
  • Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
  • SUNLIGHT study
  • Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study
Tagged